AU Patent

AU2018222947B2 — Progesterone Formulations

Assigned to TherapeuticsMD Inc · Expires 2020-06-18 · 6y expired

What this patent protects

120 100 so 440 / - S- Ex sg nProdo j401 0 10 20 30 40 50 60 70 Tnie WMirutes) FG. 4 Pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized pmgesterone are disclosed, wherein the ultra-micronized progesterone is combined with …

USPTO Abstract

120 100 so 440 / - S- Ex sg nProdo j401 0 10 20 30 40 50 60 70 Tnie WMirutes) FG. 4 Pharmaceutical formulations for oral use in hormone replacement therapy comprising ultra-micronized pmgesterone are disclosed, wherein the ultra-micronized progesterone is combined with a suitable excipient. The preferred excipients comprise medium chain fatty acid-glycol esters and a nonionic surfactant comprising a polyethylene glycol fatty acid ester. In some embodiments C8 to C18 fatty acid esters of glycerol and polyethylene glycol are the preferred nonionic surfactants.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018222947B2
Jurisdiction
AU
Classification
—
Expires
2020-06-18
Drug substance claim
No
Drug product claim
No
Assignee
TherapeuticsMD Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.